Monoclonal antibodies have been generated to the unique distal sugar epitopes on the oligosaccharide haptens of the glycopeptidolipid antigens of clinically prominent members of the Mycobacterium avium serocomplex. Thus, antibodies are described that recognize the distal 0-acetyl-Ot-L-rhamnopyranosyl residue of the specific glycopeptidolipid of M. avium serovar 1, the 4-0-acetyl-2,3-di-O-methyl-a-L-fucopyranose of serovar 2, the 4- 
, and the 4-0-acetyl-2,3-di-0-methyl-a-L-fucopyranosyl-(1-+4)-p-D-glucuronopyranosyl unit of serovar 9. Epitope definition was arrived at through use of the pure, chemically defined glycopeptidolipid antigens and neoglycoproteins containing the chemically synthesized distal sugars of some select serovars. These monoclonal antibodies combined with the already published information on the structure of the antigen determinants and the tools used to arrive at these structures provide powerful means for fundamental studies on the role of these antigens in immunopathogenesis and for the precise mapping of the epidemiology of opportunistic infections caused by M. avium.
The recent resurgent interest in members of the Mycobacterium avium complex arises from their occurrence as opportunistic pathogens in many persons with acquired immunodeficiency syndrome (AIDS) (40) , although these atypical mycobacteria have long been associated with pulmonary and other organ infections (38) . Over the past 10 years, we have been defining in precise detail the surface antigens that differentiate the 28 serovars that comprise M. avium and M. intracellulare (the M. avium complex) and the three serovars that comprise M. scrofulaceum (3) . These antigens are glycopeptidolipids related to mycoside C and, accordingly, are composed of a glycosylated lipopeptide core, fatty acyl-D -phenylalanine -D -allothreonine -D -alanine -L -alaninyl -0 -(3,4-di-O-methyl-a-L-rhamnopyranoside), to which a haptenic oligosaccharide is linked at the threonine substituent (see Fig. 3 ); this oligosaccharide unit is the source of the dominant immunogenicity of members of the M. avium complex, i.e., their characteristic agglutinability and type specificity (5) . While most of our published work is on the chemistry and antigenicity of these unusual oligosaccharides (2, 4, 7, 9, 11, 12, 28, 29) , we have also been applying the methods developed in the course of these studies to the identification and differentiation of M. avium complex serovars obtained from individuals with other underlying medical problems (6, 37, 39) . In this report, we describe the preparation of monoclonal antibodies to the unique sugar epitopes of the prominent M. avium complex serovars and identification of the specificities of these antibodies.
( 
MATERIALS AND METHODS
Mycobacteria. All serovars of the M. avium complex were from the authenticated collection described previously (37) . M. avium complex serovar 1, strain 11907-300; M. avium complex serovar 2, strain 14141-1395; M. avium complex serovar 4, strain 13528-1079; M. avium complex serovar 8, strain SJB no. 2; and M. avium complex serovar 9, strain Watson, were the major immunogens. Bacterial cultures were grown in 7H11 medium (Difco Laboratories, Detroit, Mich.) supplemented with oleic acid-albumin-dextrose-catalase (16) (Pasco Labs, Wheatridge, Colo.) before use.
Preparation of antibodies and relevant protocols. (i) Immunization of mice. Several different immunization procedures were used, depending on the serovar, the laboratory, and the investigator. For example, in the case of M. avium complex serovar 9, BALB/c mice, 6 to 8 weeks old, were primed intraperitoneally with whole washed heat-killed bacteria (50 pug in 50 [lI of sterile saline) in a suspension with an equal volume of incomplete Freund adjuvant. On days 14 and 21 after priming, identical boosts were given. At about day 20, the mice were bled and individual sera were tested in enzyme-linked immunosorbent assays (ELISA) for reactivity against an unfractionated preparation of the glycopeptidolipids (GPLs) from serovar 9 (GPL-9). The animal presenting the highest antibody response was given a final intravenous injection of 100 ,ug of lyophilized bacteria suspended in phosphate-buffered saline (PBS) (0.1 ml). On (18, 20, 24 Typing of mouse monoclonal antibody heavy chains was done by a variation of the assay described above. The second antibody in this case consisted of a panel of biotinylated rabbit antiserum rendered specific for mouse immunoglobulin heavy chains ('Y1, Y2a, Y2b' Y3, or ,u chains), which was followed by horseradish peroxidase-conjugated streptavidin.
(v) Inhibition assays. Inhibition assays were performed in the plate ELISA system by preincubating the monoclonal antibody or rabbit antiserum at a predetermined dilution with different amounts of test inhibitors before dispensing the antibody into quadruplicate wells on antigen-coated plates. The preincubations were carried out in 10% normal goat serum in PBS-0.1% Tween for 16 h at 4°C. Inhibitor concentrations are expressed as micrograms of inhibitor per well.
(vi) Dot blot and thin-layer chromatography (TLC) immunoassays. Immunoassays on nitrocellulose sheets (TransBlot sheets; Bio-Rad Laboratories, Richmond, Calif.) were performed in a manner analogous to plate assays, with the following changes. Total lipids were suspended in PBS by using a Bransonic 12 pan sonicator (Branson Sonic Power Co., Shelton, Conn.) at 50 ,ug/ml (purified glycolipids at 10 ,ug/ml), and 100 ,u was applied as a spot on nitrocellulose sheets by using a manifold (Mini Blot; Schleicher & Schuell, Inc., Keene, N.H.). The sheet was then blocked with 2% polyvinyl pyrrolidone (PVP-40; Sigma) in PBS for at least 2 h. The sheet was cut into strips, and each strip was immersed in antibody in the form of either murine hybridoma culture fluid or rabbit antiserum. After 1 to 2 h of incubation, strips were washed in a large excess of PBS-0.1% Tween for O(CH2)8COOMe 
10 min and immersed in second antibody-horseradish peroxidase for 20 min. After a second 10-min wash, the strips were immersed for color development. To each 10 ml of PBS was added 6.0 mg of 4-chloro-1-naphthol color reagent (Bio-Rad) in 2 ml of CH30H and 40 [lI of 30% H202. The development of dark purple spots was stopped by transferring the nitrocellulose to water. Immunoassays on TLC plates were conducted as described by Minnikin et al. (30) . Preparation of GPL antigens. Lipids were extracted from dry bacterial harvests with CHCl3-CH30H (2:1 [volvol]) at 50°C (5). Solvent was removed from extracts by flash evaporation, and the ensuing residue was partitioned between the two phases arising from a mixture of CHCl3-CH30H-H20 (4:2:1 [vol/vol/vol]). The lipids in the lower CHCl3 phase are referred to as total or whole lipid. All of the M. avium complex GPLs are alkali stable, although the glycosyl substituents may be acetylated to various extents (5, 17) ; accordingly, when lipid preparations are treated with base to destroy nonspecific acylglycerols, the native GPLs, if acetylated, become deacetylated (5). Nevertheless, for ease of purification, the total lipid preparations were usually treated with 0.2 N NaOH in CH30H for 30 min at 37°C and washed. The product is referred to as unfractionated GPLs. Procedures for the purification of the individual specific GPLs from individual serovars have been described previously (11, 12, 29) . All purification procedures involved silica gel column chromatography in CHCl3 with increasing concentrations of CH30H, depending on the relative polarity of the specific GPL, followed by preparative TLC. In addition, the naturally acetylated GPLs were purified as described previously (29) from total lipid preparations that had not been subjected to alkali treatment. The monoacetylated GPL-9 (GPL-9I) from M. avium complex serovar 9 was an exception in that some of it survived mild alkali treatment; it was finally purified by preparative TLC in CHCl3-CH30H-H20 
is common to all serovars, we concluded that the specific antigen determinant on GPL-4 is inherent to the nonreducing-end disaccharide,
Our approach to the synthesis of this specific terminal glycobiose unit involved a block synthesis; the disaccharide unit was then elaborated on the 8-methoxycarbonyloctyl aglycon, a strategy used previously in preparing the M. leprae-specific neoantigens (13, 14) ; because of the sensitivity of the spacer arm to various reaction conditions, a block synthesis approach facilitated the stability of the aglycon. In the terminal stages of this synthesis, the 8-methoxycarbonyloctyl 0-( Fig. 1 ) was converted to its hydrazide (compound II in Fig. 1 ) as described previously (13, 14) ; freeze-dried hydrazide was then converted to its acyl azide and immediately coupled to the carrier protein BSA (13) . The resulting neoglycoconjugate was dialyzed and purified by gel filtration on Sephadex G-75 (13) . An incorporation of 30 mol of carbohydrate per mol of BSA was achieved. Full details of the synthesis of this neoantigen will be described separately.
(ii) Synthesis of a neoantigen containing the terminal monosaccharide of the M. avium serovar 4-specific GPL (monosaccharide-containing neoantigen-4). Allyl 2,3-0-isopropylidene-4-0-methyl-a-L-rhamnopyranoside was synthesized (21), purified by column chromatography, and hydrolyzed to give allyl-4-0-methyl-a-L-rhamnopyranoside. By the procedure of Bernstein and Hall (1), the appropriate glycoconjugate was prepared from the allyl glycoside and BSA. The neoglycoconjugate was purified by gel filtration on Sephadex G-25 (13 drate (13) . Full details of this conjugation procedure and of this neoantigen synthesis will be described separately.
(iii) Synthesis of neoantigens containing the terminal monosaccharide or the monoacetylated terminal monosaccharide of the M. avium serovar 9-specific GPL (acetylated or nonacetylated neoantigen-9). The starting point for these syntheses was the allyl 2,3-di-0-methyl-a-L-fucopyranoside; the full details of its synthesis have been described by Takeo et al. (36) . In addition, a portion of this material was acetylated by using pyridine and acetic anhydride. Both of these monosaccharide derivatives were converted to their corresponding neoglycoconjugates by using the method described above. (21) . The ailyl group was protected by epoxidation, forming epoxypropyl glycoside using m-chloroperoxybenzoic acid. Ketalization using 3,4-dimethoxyacetophenone gave the 4,6-0-ketal which upon RuO4 oxidation gave its 4,6-0-(1'-carboxymethylethylidene) derivative (10) . The allyl glycoside needed for the preparation of the glycoconjugate was regenerated from the epoxypropyl glycoside by using 3-methyl-2-selenoxobenzthiazole. Transesterification of this product gave the title compound (i.e., the allyl glycoside). The detailed synthesis of this particular epitope will be published elsewhere. RESULTS Distribution of M. avium serovars in acquired immunodeficiency syndrome patients. The results of the application of a combination of seroagglutination of whole cells (35) , ELISA (39) , and comparative TLC of the extracted GPL antigens (6) to over 1,000 M. avium complex isolates from acquired immunodeficiency syndrome patients has shown that serovars 1, 2, 4, 8, and 9 predominate (results not shown). This and other corresponding information (22, 29) prompted us to prepare monoclonal antibodies to the type-specific GPL antigens of these particular serovars in order to facilitate their identification. Figure 2 shows a thin-layer chromatogram of the purified GPL typing antigens from these predominant serovars. The different polarities of the purified GPLs reflect the marked differences in the structures of the terminal segments of the oligosaccharide haptens. The structures of the GPL antigens of serovars 1, 2, 4, 8, and 9 are summarized in Fig. 3 ; we have recently published the structures of the oligosaccharide haptens of 12 of the 28 known M. avium complex serovars (2, 3) . It has been reasoned (3) that since the lipopeptide core and the reducing-end disaccharide of the oligosaccharide segments of the GPL antigens are invariant from one serovar to another, then the nonreducing-end segment of the variable oligosaccharide must contain the respective antigen determinants. We hoped to match the nonreducing, distal, typespecific segments of the oligosaccharide haptens with corresponding antibodies and thereby provide the means for optimal differentiation and identification of clinically significant M. avium complex isolates.
Monoclonal antibodies to the sugar determinants of the prominent M. avium serovars. Cell lines secreting antibodies to these particular serovars were raised in many separate Core Structure for all Serovars: fusion experiments in the Colorado and Amsterdam laboratories by using a variety of immunization strategies ( Table  1) . The cell lines listed in Table 1 arising from an immunization with M. avium serovar 9 were all independent isolates from a fusion of SP2/o with mouse spleen cells following immunization with whole killed bacteria; no added inoculation with GPL preparations was used during the immunization. Eighteen cell lines were generated, eleven of which were distinct and which secreted antibodies reactive to the unfractionated GPLs of serovar 9. Similarly, cell lines 1105.1, 1107.1, and 1206.1 (not listed in Table 1) were raised in a different fusion after immunization with whole M. avium serovar 8 cells and by screening against unfractionated GPLs of serovar 8; however, these latter lines were not used for precise definition of the specific epitope of serovar 8. Instead, higher-titer antibodies were obtained by intravenous immunizations with a mixture (2:1 [wt/wt]) of whole unfractionated GPLs from M. avium serovar 8 and whole cells, respectively (Table 1 ).
In the case of M. avium complex serovar 4, the Amsterdam laboratory was highly successful in raising serovarspecific antibodies by using whole bacilli as the immunogen as described previously (26) Table 1 were specific to the GPLs of serovar 9; none cross-reacted with the GPL antigens of the other 31 serovars (Fig. 4) . The antigen preparation used in the original screen for all of the anti-GPL-9 antibodies was unfractionated GPLs from serovar 9. The crude GPL-9 preparation was fractionated on a column of Florisil, and the partially purified lipids as they emerged from the column were subjected to TLC and ELISA against four of the anti-GPL-9 monoclonal antibodies 2.0- quantity of glycolipid was applied to nitrocellulose and the dot ELISA protocol was applied by using four of the available antibodies. (Fig. 5) . Two GPLs, GPL-91 and GPL-91I, were at once obvious on the thin-layer plates (Fig. 5A) , and it seemed from their reactions with the antibodies that only the fastermigrating GPL-91 was antigenic (Fig. SB) ; note how the later 20% CH30H eluates, those which contained primarily GPL-911, barely reacted with the antibodies. Indeed, when GPL-91 and GPL-911 were fully purified by preparative TLC and reacted against this set of monoclonal antibodies in plate ELISA, only GPL-91 was shown to be reactive ( Table 2) . The results of inhibition ELISA in which monoclonal antibody 5210 was preincubated with either GPL-9I or GPL-911 prior to reaction with GPL-91 are shown in Fig. 6A . The decrease in ELISA absorbance which occurred after preincubation of the antibody with GPL-9I indicates that the antibody had bound to GPL-91 during the preincubation, and the unchanging absorbance readings after preincubation of antibody with GPL-91I demonstrated that the antibodies did not bind to GPL-911 during the preincubation since they were still capable of reaction with the antigen on the ELISA plate. Polyclonal rabbit sera raised to whole cells of M. antibodies. Rabbit antiserum specific for serovar 9, prepared as described previously (35) , was serially diluted and tested in ELISA against either GPL-9I or GPL-911 (5 ng/well). Other conditions are described in the text. avium serovar 9 demonstrated an identical reactivity pattern (Fig. 6B) .
Recently, using GPL-911 as the source of the oligosaccharide hapten, Chatterjee et al. (11) established the structure of the oligosaccharide segment of the specific GPL of serovar 9 (Fig. 3) , and we had assumed that the distal 2,3-di-0-Me-L-Fucp(al--*4)-D-GlcAp unit is the specific epitope of serovar 9. However, now that we have found that GPL-911 is inactive, earlier speculation of ours (5, 11) seemed important, i.e., that GPL-9I may be a minor, acetylated form of GPL-II which, due perhaps to the particular location of the O-acetyl function(s), survived the mild alkali treatment applied in the work up of the crude GPLs. Accordingly, the 360 MHz 'H NMR spectra of GPL-91 and GPL-9II were compared (Fig. 7) . Only the spectrum of GPL-91 contained the signal (5 2.18) of an acetyl function (Fig. 7B) , a signal which was absent from GPL-911 (Fig. 7A ). Two-dimensional 'H NMR located this single acetyl function on the C-4 of the nonreducing-end 2,3-di-O-Me-fucose unit (results not shown). Furthermore, the approach described in detail by Chatterjee et al. (11) established that the oligosaccharide unit of GPL-91 was identical to that of GPL-91I. Accordingly, the that the characteristic GPL of M. avium serovar 4 ( Fig. 3) also occurs in the acetylated form (29) . Since then, we have demonstrated that the acetyl function is located on the structure of the entire oligosaccharide hapten of GPL-91 is as reducing-end 6-deoxytalose residue, not on the nonreducingshown in Fig. 8 .
end 4-O-methyl-rhamnose unit (25) . The application of imThus, a combination of conventional and correlation munostaining to TLC plates directly (30) demonstrated that (COSY) 'H NMR spectroscopy combined with the availabil-both the acetylated and nonacetylated GPL-4 were recogity of an array of monoclonal antibodies and the fortunate nized equally well by monoclonal antibodies 32B8 (Fig. 11) and 33F7. Accordingly, it appeared that if the O-acetyl function is positioned well away from the nonreducing sugar and the other containing the terminal disaccharide unit (4-0-methyl-ot-L-rhamnopyranosyl(1--+4)2-0-methyl-ax-L-fucopyranose); the former was synthesized in the Ontario laboratory by using an allyl linker arm and the latter was synthesized in the Colorado laboratory by using the oxynonanoyl link; the structures of these two neoantigens are shown as part of Fig. 12 . Such neoantigens are readily electrophoresable (14) . Accordingly, both were subjected to polyacrylamide gel electrophoresis, transferred to nitrocellulose, and reacted with the anti-GPL-4 monoclonal antibodies; the results from immunoblotting with 32B8 and 33F7 are shown in Fig. 13 . Only the disaccharide-containing neoantigen (4- (Fig. 13A and B) . Antibodies F85-3 and F85-5 (from the Amsterdam laboratory) behaved in a similar fashion. However, against antiwhole serovar 4 rabbit antiserum, both neoantigens reacted readily (Fig. 13C) neoantigen (Fig. 12) and antibody. Accordingly, the penultimate sugar unit of the oligosaccharide segment of the specific GPL antigen of serovar 4 contributes to the binding of a series of murine monoclonal antibodies, in contrast to polyclonal rabbit antibodies, which require merely the single 4-0-methyl-a-L-rhamnopyranosyl terminal nonreducing-end sugar.
Anti-serovar 8 monoclonal antibodies recognize a pyruvylated glucosyl epitope. The most useful anti-serovar 8 mono- clonal antibodies (2B8, SF7, and 4D7) arose in the Colorado laboratory as a result of a complex immunization strategy involving whole lipid extract and whole cells (Table 1) . Monoclonal antibodies 2B8 and SF7 showed absolute specificity for the GPL of serovar 8 (Fig. 14A) ; the slight reactivity shown against GPL-6 is due to the contamination of some isolates of M. avium serovar 6 with serovar 8.
However, antibody 4D7 recognized GPL-21 almost as effectively as it did GPL-8 (Fig. 14B) . We have already established the structure of the terminal segment of the oligosaccharide hapten of serovar 8 as 4,6(1'-carboxyethylidene)-3-O-methyl-p-D-glucopyranosyl(1--*3) (Fig. 3) demonstrated by use of the appropriate neoantigen (Fig. 15 ) synthesized in the Ontario laboratory. All of the available monoclonal antibodies (Table 2 ) and the rabbit polyclonal antibodies reacted similarly with neoantigen-8.
Monoclonal antibodies selective for the terminal glycosyl units of the specific GPLs of serovar 1 and serovar 2. Coincidentally, the simplest-named serovars also are endowed with the simplest oligosaccharide haptens (Fig. 3) . Such simple haptens apparently confer relatively low specific immunogenicity on the parental GPL and the whole serovar. For instance, immunization of 10 individual mice yielded only one animal with a serum titer of 1:320 (Table 1) . Nevertheless, suitably specific, albeit low-titer, monoclonal antibodies were generated in the Colorado laboratory (Table 1) . However, none of these antibodies reacted with the unfractionated GPLs prepared after the usual alkali treatment. However, when the naturally acetylated unfractionated 'GPLs or the pure acetylated specific GPL from serovar 1 were used, they reacted with the anti-serovar 1 monoclonal antibodies. Thus, the characteristic epitope of serovar 1 must be an 0-acetylated terminal ot-L-rhamnopyranosyl residue. Although the a-L-rhamnopyranosyl(1l-2)-linked terminal residue of GPL-1 is found in the oligosaccharide segments of the GPLs of all serovars (Fig. 3) (2) , only in the case of serovar 4 is it the terminal, nonreducing-end sugar.
Likewise, monoclonal antibody 123.4 of the IgG2a isotype (Table 1) recognized only the acetylated specific GPL from the homologous serovar 2; it did not react with the nonacetylated specific GPL-2 nor with the acetylated or nonacetylated GPLs from other serovars (results not shown). Since the 2,3-di-O-methyl-L-fucopyranose(al-->3)-L-rhamnopyranose unit is present in other GPLs (e.g., GPL-9) but represents an internal diglycosyl unit in these other serovars, then the antibody must require the 2,3-di-O-methyl-o-L-fucopyranosyl residue at the nonreducing end, and it also must be 0 acetylated at the 4-OH.
DISCUSSION
The primary goal of the present work was to generate monoclonal antibodies absolutely specific for each of the major serovars of the M. avium complex and then to apply these to the identification and classification of M. avium isolates as they arise in opportunistic infections in immunocompromised individuals and to the establishment of epidemiological trends. Others (31; Ranchoff et al., Abstr. Annu. Meet. Am. Soc. Microbiol. 1986) had generated anti-M. avium complex monoclonal antibodies with similar goals in mind and, on the basis of the selective reactivities of these antibodies with glycopeptidolipid-containing preparations, had concluded that they were directed to the said antigens. However, in a series of exhaustive studies (2, 4, 7, 9, 11, 12, 20, 29) , we had pinpointed the serotypic specificities of members of the M. avium complex as being due to differences in sugar arrangements at the distal nonreducing end of the otherwise invariant polar GPL molecule, and as the originators of this information and relevant methods, we were thus in a position to precisely define the epitopes of many of these antibodies. In the present comprehensive study, we have applied not only our knowledge of the chemistry of these surface immunogens but also the ability to synthesize corresponding neoantigens and to apply these antigens and neoantigens to a variety of relevant immunochemical protocols. Thus, from our chemistry-based perspective, the study represents an attempt at ultimate epitope definition and an effort to match each antibody with a chemically defined determinant. The practical applications of these antibodies will be described elsewhere. In a word, they are generally decidedly specific for the homologous, whole serovar and can be applied directly to bacterial cultures, thus allowing easy, rapid identification of at least half of the M. avium isolates encountered in the clinical laboratory (unpublished results). This earlier chemical ap-
on October 28, 2017 by guest http://iai.asm.org/ Downloaded from proach had identified an exceptional array of novel deoxysugars, sugar acids, amido sugars, and branched-chain sugars, all occupying the distal segment of the oligosaccharide hapten and thus, presumably, the serovar-specific epitopes. Our strategy was to match these varied and unusual sugars with equally specific antibodies and thereby bypass seroagglutination with preabsorbed rabbit sera or protocols based on protracted TLC or gas chromatography of the specific GPLs, the standard means by which members of the M. avium complex are identified. In this we have been successful, although the enterprise was protracted and involved considerable initial frustration in raising antibodies with the requisite specificities (Ranchoff, M.S. thesis). For this reason, we also included in the study antibodies raised by other investigators, apparently with greater ease, but awaiting definition of epitope; of the many surveyed, those from the Amsterdam laboratory were of consistently high titer and, generally, high absolute specificity.
There are other more fundamental lessons to be learned from this study due to the availability of detailed knowledge of the chemistry of the appropriate surface glycolipid immunogens. These glycopeptidolipids occur in both the partially 0-acetylated and completely 0-deacetylated forms (5, 17) . However, the positions or roles of these O-acetyl functions were not known in the context of the antigenicity of the parental GPLs; 0 acetylation of GPLs is clearly important in the binding of certain mycobacteriophages to the parental organism (17) . Accordingly, the observation of the role of an O-acetyl function in antibody binding when positioned on the distal sugar is important although not unexpected. Lindberg and Hellerqvist (27) first showed the importance of 0-acetyl groups in recognizing polyclonal antibodies to the O antigens of enteric bacteria, and the point has been repeatedly demonstrated since. Some of the anti-M. avium antibodies generated by Nishimori et al. (31) also showed a marked preference for GPLs isolated without the use of alkali, as described herein and elsewhere (5) , and thus presumably 0 acetylated. The type of specificity for steric and absolute configuration, anomeric linkage, and specifically located acetoxy and methoxy functions demonstrated in this and other work (unpublished results) has also been demonstrated for the enormous collection of monoclonal antibodies raised to assorted glycosylceramides (8, 23) . In this present study, we also describe murine monoclonal antibodies that selectively react with the 4,6-pyruvylated-3-0-methyl-D-glycosyl unit of the serovar 8-specific GPL. In an exhaustive study, Rao et al. (34) had described human monoclonal IgM proteins that distinguish between 3,4-pyruvylated-D-galactose and 4,6-pyruvylated D-glucose. Some of the antibodies described herein (especially those from the Amsterdam laboratory) that apparently require an 0-acetyl substituent on the innermost 6-deoxytalose residue are also reminiscent of other antibodies described in the literature. Nudelman et al. (32) have described a murine monoclonal IgM antibody whose specificity is determined by the reducing-end sugar on the tetrasaccharide hapten of a ganglioside. Yet another antibody described by this group showed strict selectivity for the linkage position within an otherwise identical terminal glycobiose unit (33) .
Much more fundamental information on the precise structural requirements for the binding of carbohydrate determinants to murine monoclonal antibodies will undoubtedly emerge as we continue to match the exceptional diversity of structures within the glycopeptidolipids, lipooligosaccharides, and phenolic glycolipids (3) of Mycobacterium spp. with corresponding monospecific antibodies. Indeed, monoclonal antibodies to the phenolic glycolipid I of Mycobacterium leprae (19) show an exquisite specificity for the number and the positions of the methoxy groups on the distal 3,6-di-0-methyl-a-D-glycopyranosyl unit (14, 15, 19) . Clearly, however, for present clinical purposes the present collection of antibodies specific to the most prominent M. avium serovars fulfills a pressing need.
